Immunotherapy is one of the most important breakthroughs in cancer treatment, and compared with standard therapies, immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) significantly prolong overall survival (OS) in patients with a wide range of tumor types1,2. The gene discussed is PDCD1; the disease is cancer.